Status: Recruiting
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
The aim of CABOTEM study is to demonstrate the safety and activity of the Cabozantinib and Temozolomide combination in Lung and GEP-NENs patients, progressing after a first line therapy, including target therapies (everolimus, sunitinib) and / or chemotherapy, in the approved setting.
Participants needed: 35
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: National Cancer Institute, NaplesUpdated: Jun 18, 2024Locations: 1
Eligibility criteria
18 years and older patients. [+18]
Receipt of any type of anticancer therapy within 4 weeks before study entry. [+19]